Bafna Pharmaceuticals Ltd (BAFNAPH) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 852453,
    "name": "Bafna Pharma.",
    "stock_name": "Bafna Pharma.",
    "full_name": "Bafna Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/bafna-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "119.90",
    "chg": -1.95,
    "chgp": "-1.6%",
    "dir": -1,
    "prev_price": "121.85",
    "mcapval": "285.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532989,
    "symbol": "BAFNAPH",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE878I01022",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "4.26 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/bafna-pharma-852453-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3744340",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_only_sellers_3744340.png",
        "date": "2025-12-03 13:35:44",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure in recent sessions, with the stock registering consecutive declines and a notable absence of buyers today. The pharmaceutical company’s shares have underperformed the broader market and sector indices, signalling distress selling and heightened market caution."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Lower Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3741826",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_only_sellers_3741826.png",
        "date": "2025-12-02 13:20:46",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock hitting a lower circuit and an absence of buyers in the queue. This development signals distress selling and raises concerns about the stock's immediate market sentiment."
      },
      {
        "title": "How has been the historical performance of Bafna Pharma.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-bafna-pharma-3739329",
        "imagepath": "",
        "date": "2025-12-01 23:26:00",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Operating Performance Trends</strong></p>\n<p>Bafna Pharma’s net sales have seen a significant contraction over the past seven years. From a peak exceeding ₹185 crores in the fiscal year ending March 2014, sales declined steadily to ₹43.36 crores by March 2019. This downward trend reflects a substantial reduction in the company’s core operating income, which also fell from ₹185.34 crores in 2014 to ₹43.36 crores in 2019. The company’s other operating income was negligible in recent years, except for a notable ₹41.11 crores in 2015, which temporarily bolstered total operating income.</p>\n<p>Cost management has been a persistent issue. Raw material costs and purchase of finished goods have fluctuated but remained substantial relative to sales, contributing to negative operating marg..."
      },
      {
        "title": "Bafna Pharmaceuticals Surges with Unprecedented Buying Interest, Poised for Multi-Day Upper Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-hits-upper-circuit-amid-unprecedented-buying-interest-3738625",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_only_buyers_3738625.png",
        "date": "2025-12-01 11:31:19",
        "description": "Bafna Pharmaceuticals has captured market attention with extraordinary buying momentum, registering an upper circuit with exclusively buy orders in the queue. This rare phenomenon signals robust investor enthusiasm and the potential for a sustained multi-day circuit scenario, underscoring the stock’s remarkable performance in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-intense-selling-pressure-amid-lower-circuit-lockdown-3733804",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BafnaPharmaceut_only_sellers_3733804.png",
        "date": "2025-11-27 14:40:46",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock hitting a lower circuit and registering only sell orders in the queue. This distress selling signals a challenging phase for the company as it continues to underperform relative to the broader market and its sector peers."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3731172",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BafnaPharmaceut_only_sellers_3731172.png",
        "date": "2025-11-26 10:40:50",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure, with the stock registering a decline of 1.98% today and exhibiting a persistent downtrend over the past week. The absence of buyers and a queue dominated solely by sell orders signal distress selling, raising concerns about the stock’s near-term momentum within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Why is Bafna Pharma. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-bafna-pharma-fallingrising-3729947",
        "imagepath": "",
        "date": "2025-11-26 01:19:11",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Bafna Pharmaceuticals has experienced a notable pullback over the past week, with its stock price declining by 7.49%, significantly underperforming the broader Sensex index, which remained nearly flat with a marginal 0.10% loss during the same period. This recent weakness contrasts with the stock’s impressive longer-term performance, having delivered a year-to-date return of 110.78%, far outpacing the Sensex’s 8.25% gain. Over the past year, the stock has also surged by 97.27%, compared to the Sensex’s 5.59%, underscoring its strong growth trajectory despite the current short-term setback.</p>\n<p>The stock’s five-year returns of 127.11% also highlight its sustained outperformance relative to the benchmark’s 93.00%, indicating that the ..."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-intense-selling-pressure-amid-lower-circuit-lockdown-3729151",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BafnaPharmaceut_only_sellers_3729151.png",
        "date": "2025-11-25 14:40:47",
        "description": "Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock registering a lower circuit and an absence of buyers in the queue. This development follows a series of consecutive declines, signalling distress selling within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-faces-intense-selling-pressure-amid-lower-circuit-lockdown-3725478",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BafnaPharmaceut_only_sellers_3725478.png",
        "date": "2025-11-24 12:20:59",
        "description": "Bafna Pharmaceuticals Ltd has encountered significant selling pressure in recent sessions, with the stock registering a consecutive three-day decline and exhibiting a complete absence of buyers today. This pattern signals distress selling and heightened market caution within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 253,
    "sid": "852453",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/bafna-pharmaceuticals-852453"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Credit Rating",
      "datetime": "23-Jan-2026",
      "details": "We hereby inform you that the Outlook of the Credit Ratings assigned to the Bank loan facilites of the Company has been revised by ICRA Limited.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "09-Jan-2026",
      "details": "Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the Quarter ended December 31 2025.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "26-Dec-2025",
      "details": "Intimation for Closure of Trading Window.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bafna Pharmaceuticals Ltd has declared <strong>6%</strong> dividend, ex-date: 19 Sep 13",
          "dt": "2013-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-12-03 13:35:44

Bafna Pharmaceuticals has encountered significant selling pressure in recent sessions, with the stock registering consecutive declines and a notable absence of buyers today. The pharmaceutical company’s shares have underperformed the broader market and sector indices, signalling distress selling and heightened market caution.

Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Lower Circuit

2025-12-02 13:20:46

Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock hitting a lower circuit and an absence of buyers in the queue. This development signals distress selling and raises concerns about the stock's immediate market sentiment.

How has been the historical performance of Bafna Pharma.?

2025-12-01 23:26:00

Revenue and Operating Performance Trends Bafna Pharma’s net sales have seen a significant contraction over the past seven years. From a peak exceeding ₹185 crores in the fiscal year ending March 2014, sales declined steadily to ₹43.36 crores by March 2019. This downward trend reflects a substantial reduction in the company’s core operating income, which also fell from ₹185.34 crores in 2014 to ₹43.36 crores in 2019. The company’s other operating income was negligible in recent years, except for a notable ₹41.11 crores in 2015, which temporarily bolstered total operating income. Cost management has been a persistent issue. Raw material costs and purchase of finished goods have fluctuated but remained substantial relative to sales, contributing to negative operating marg...

Bafna Pharmaceuticals Surges with Unprecedented Buying Interest, Poised for Multi-Day Upper Circuit

2025-12-01 11:31:19

Bafna Pharmaceuticals has captured market attention with extraordinary buying momentum, registering an upper circuit with exclusively buy orders in the queue. This rare phenomenon signals robust investor enthusiasm and the potential for a sustained multi-day circuit scenario, underscoring the stock’s remarkable performance in the Pharmaceuticals & Biotechnology sector.

Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-11-27 14:40:46

Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock hitting a lower circuit and registering only sell orders in the queue. This distress selling signals a challenging phase for the company as it continues to underperform relative to the broader market and its sector peers.

Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-11-26 10:40:50

Bafna Pharmaceuticals has encountered significant selling pressure, with the stock registering a decline of 1.98% today and exhibiting a persistent downtrend over the past week. The absence of buyers and a queue dominated solely by sell orders signal distress selling, raising concerns about the stock’s near-term momentum within the Pharmaceuticals & Biotechnology sector.

Why is Bafna Pharma. falling/rising?

2025-11-26 01:19:11

Recent Price Movement and Market Context Bafna Pharmaceuticals has experienced a notable pullback over the past week, with its stock price declining by 7.49%, significantly underperforming the broader Sensex index, which remained nearly flat with a marginal 0.10% loss during the same period. This recent weakness contrasts with the stock’s impressive longer-term performance, having delivered a year-to-date return of 110.78%, far outpacing the Sensex’s 8.25% gain. Over the past year, the stock has also surged by 97.27%, compared to the Sensex’s 5.59%, underscoring its strong growth trajectory despite the current short-term setback. The stock’s five-year returns of 127.11% also highlight its sustained outperformance relative to the benchmark’s 93.00%, indicating that the ...

Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-11-25 14:40:47

Bafna Pharmaceuticals has encountered significant selling pressure today, with the stock registering a lower circuit and an absence of buyers in the queue. This development follows a series of consecutive declines, signalling distress selling within the Pharmaceuticals & Biotechnology sector.

Bafna Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-11-24 12:20:59

Bafna Pharmaceuticals Ltd has encountered significant selling pressure in recent sessions, with the stock registering a consecutive three-day decline and exhibiting a complete absence of buyers today. This pattern signals distress selling and heightened market caution within the Pharmaceuticals & Biotechnology sector.

View All News